Agile Therapeutics, Inc.
AGRX
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.33% | 49.91% | -9.56% | 121.92% | 158.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.33% | 49.91% | -9.56% | 121.92% | 158.84% |
| Cost of Revenue | -35.15% | -16.13% | 32.55% | 73.82% | 3.41% |
| Gross Profit | 27.66% | 122.98% | -39.27% | 165.38% | 3,143.81% |
| SG&A Expenses | -17.47% | -18.79% | -38.88% | -10.69% | -27.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.70% | -19.47% | -29.50% | 0.70% | -21.41% |
| Operating Income | 46.43% | 58.90% | 41.09% | 47.27% | 55.03% |
| Income Before Tax | -211.68% | 123.82% | -13.71% | 86.53% | 26.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -211.68% | 123.82% | -13.71% | 86.53% | 26.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -211.68% | 123.82% | -13.71% | 86.53% | 26.30% |
| EBIT | 46.43% | 58.90% | 41.09% | 47.27% | 55.03% |
| EBITDA | 47.45% | 59.88% | 41.77% | 46.72% | 53.44% |
| EPS Basic | 19.54% | 104.69% | 68.36% | 96.62% | 96.24% |
| Normalized Basic EPS | 19.55% | 104.69% | 68.36% | -103.86% | 96.24% |
| EPS Diluted | 19.54% | 104.69% | 68.31% | 96.62% | 96.24% |
| Normalized Diluted EPS | 19.55% | 104.69% | 68.36% | -103.86% | 96.24% |
| Average Basic Shares Outstanding | 287.40% | 407.88% | 259.37% | 298.66% | 1,862.08% |
| Average Diluted Shares Outstanding | 287.40% | 407.88% | 259.37% | 298.66% | 1,862.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
